FDA May Clear First COVID-19 Vaccine For Younger Kids, Probably Today: NYT - Pfizer (NYSE:PFE), BioNTech (NASDAQ:BNTX)

The FDA is likely to authorize Pfizer Inc PFE / BioNTech SE's BNTX COVID-19 vaccine for use in children ages 5-11 on Friday, The New York Times reports, citing people familiar with the agency's planning.
About 28 million children would be eligible for the vaccine, with two injections three weeks apart at one-third of the adult dose.
The newspaper said if the Centers for Disease Control and Prevention signs off, which is expected, the children could start getting shots as early as November 3, Wednesday.
The CDC officials said it would be hard to narrow eligibility, and the FDA's advisory panel endorsed the pediatric dose to the entire age group.
Related Link: FDA's Adcomm Almost Unanimously Back Pfizer/BioNTech's COVID-19 Shots For Younger Kids.
Yesterday, the U.S. government purchased 50 million more doses of Pfizer / BioNTech's COVID-19 vaccine.
The doses are expected to be delivered by April 2022.
Price Action: PFE shares are up 0.87% at $43.56, while BNTX stock is down 2.69% at $276.33 during the market session on the last check Friday.
Photo by x3 from Pixabay